NCT lookup

Inclusion Criteria:

* Children of either gender aged between 6 months and 5 years, at Baseline/Randomisation (Visit 2) inclusive.
* For children ≥1 year of age, ≥4 RTIs (as reported by parents or LAR of subject), including ≥2 episodes of wLRIs (including ≥1 triggering hospitalisation or medical visit) within 12 months prior to enrolment.

OR

* For children \<1 year of age, ≥2 RTIs (as reported by parents or LAR of subject), including ≥1 episode of wLRIs (including ≥1 triggering hospitalisation or medical visit) within 6 months prior to enrolment.
* Parents or LAR of subject have provided the appropriate written informed consent. Written informed consent must be provided before any study-specific procedures are performed including screening procedures.

Exclusion Criteria:

* Anatomic alterations of the respiratory tract.
* Other chronic respiratory diseases (e.g., tuberculosis, cystic fibrosis).
* Any autoimmune disease.
* HIV infection or any type of congenital or iatrogenic immune deficiency (including IgA deficiency).
* Known severe congenital heart disease.
* Haematologic diseases.
* Liver or kidney failure.
* New-borns before 34 weeks of gestational age.
* Malnutrition as per World Health Organization (WHO) definition.
* Any known neoplasia or malignancy.
* Treatment with the following medications:

  1. Injection or oral administration of steroids within 4 weeks prior to study enrolment.
  2. Previous and/or concomitant immunosuppressants, immunostimulants, or gamma globulins within 6 months prior to study enrolment.
* Previous use within last 6 months of enrolment or ongoing use of bacterial lysates.
* Any major surgery within the last 3 months prior to study enrolment.
* Known allergy or previous intolerance to investigational medicinal products (IMP).
* Any other clinical conditions, that in the opinion of the Investigator, would not allow safe completion of the clinical study.
* Other household members have previously been randomised in this clinical study.
* Subjects' families expected to relocate out of study area within 24 months of the initiation of the study.
* Currently enrolled in or has completed any other investigational device or drug study or receiving other investigational agent(s) within \<30 days prior to screening.
* Parents or legally acceptable representative (LAR) who do not have access to internet connection.
* Wheezing documented to be caused by gastroesophageal reflux.

• München, Bavaria, Germany
• Schönau am Königssee, Bavaria, Germany
• Hanover, Lower Saxony, Germany
• Bochum, North Rhine-Westphalia, Germany
• Cologne, North Rhine-Westphalia, Germany
• Düsseldorf, North Rhine-Westphalia, Germany
• Mönchengladbach, North Rhine-Westphalia, Germany
• Wesel, North Rhine-Westphalia, Germany
• Lübeck, Schleswig-Holstein, Germany
• Szeged, Csongrád megye, Hungary
• Balassagyarmat, Hungary
• Budapest, Hungary
• Budapest, Hungary
• Gyula, Hungary
• Miskolc, Hungary
• Parma, Parma, Italy
• Pavia, Pavia, Italy
• Pisa, Pisa, Italy
• Bari, Italy
• Bergamo, Italy
• Krakow, Lesser Poland Voivodeship, Poland
• Tarnów, Lesser Poland Voivodeship, Poland
• Lublin, Lublin Voivodeship, Poland
• Lodz, Lódzkie, Poland
• Bialystok, Podlaskie Voivodeship, Poland
• Częstochowa, Silesian Voivodeship, Poland
• Siemianowice Śląskie, Silesian Voivodeship, Poland
• Krakow, Poland
• Rzeszów, Poland
• Skierniewice, Poland
• + 12 more on CT.gov